Clinical Trial

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-06-01; most recent amendment 2025-01-10.
Status change: Recruiting → Active, Not Recruiting 2025-01-06
Status change: Not Yet Recruiting → Recruiting 2023-06-02
Trial Details
NCT Number NCT05885464
Lead Sponsor Beam Therapeutics Inc.
Conditions Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Enrollment 5 participants
Start Date 2023-05-25
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-13